Sirnaomics said this week that it has licensed a polypeptide nanoparticle delivery technology developed at the University of Maryland Medical School.
"The licensing agreement grants Sirnaomics exclusive rights to a patent covering use of histidine-lysine polymer for siRNA therapeutics in the areas of wound healing and ocular diseases," the company said.
"Licensing the histidine-lysine polymer nanoparticle technology is rooted in our long-time experience and in-depth understanding of this unique class of polypeptides as an siRNA delivery vehicle," Sirnaomics President and CEO Patrick Lu said in a statement. "We are currently engaging in several similar collaborative efforts and we believe that this is a great way to create value and ensure the credibility of a novel technology."